Frequency of the anti-glutamic acid decarboxylase immunological marker in patients with diabetes duration longer than three years in southern Brazil
Keywords:
Antibodies, Diabetes mellitus, type 1, Autoimmunity, Chronic disease, IncidenceAbstract
CONTEXT AND OBJECTIVE: The anti-GAD (glutamic acid decarboxylase) antibody is considered to be an important marker for type 1 diabetes mellitus (DM1), with frequency that varies depending on the population studied and the duration of the disease. Therefore, the aim of this study was to determine the frequency of this autoantibody in a group of patients in southern Brazil with DM1 that had been diagnosed more than three years previously. DESIGN AND SETTING: Analytical cross-sectional study with a control group conducted at the Biomedicine Laboratory of Universidade Feevale. METHODS: This study was conducted between June 2007 and December 2008, and 109 individuals were enrolled during this period. Fifty-eight were DM1 patients and 51 were individuals free from DM1 and without any history of diabetes, who constituted the control group. RESULTS: In the DM1 group, the mean age was 27 ± 1.7 years and 50% were men. The mean fasting blood glucose in the DM1 group was 208 ± 15 mg/dl and mean HbA1c (glycosylated hemoglobin) was 8.7 ± 0.25%. In the control group, the mean fasting blood glucose and HbA1c were 82 mg/dl and 5.0% respectively. Thirty-seven individuals with DM1 (63.8%) were positive for anti-GAD, and this proportion was significantly larger than in the control group. CONCLUSIONS: These results show the high prevalence of anti-GAD in the population of diabetic patients in southern Brazil, thus indicating that the antibody was still present a long time after the disease had been diagnosed.
Downloads
References
Daneman D. Type 1 diabetes. Lancet. 2006;367(9513):847-58.
Fernandes APM, Pace AE, Zanetti ML, Foss MC, Donadi EA. Fatores imunogenéticos associa- dos ao diabetes mellitus do tipo 1 [Immunogenetic factors associated with type 1 diabetes mellitus]. Rev Latinoam Enferm. 2005;13(5):743-9.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30 Suppl 1:S42-7.
Dantas JR, Almeida MH, Barone B, et al. Avaliação da função pancreática em pacientes com diabetes melito tipo 1 de acordo com a duração da doença [Pancreatic function assessment in type 1 diabetes mellitus patients according to disease duration]. Arq Bras Endocrinol Metab. 2009;53(1):64-71.
Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in in- sulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151-6.
Silva MER, Ursich MJM, Rocha DM, et al. Diabetes autoimune em adultos: características clínicas e autoanticorpos [Autoimmune diabetes in adults: clinical characteristics and an- toantibody]. Arq Bras Endocrinol Metab. 2003;47(3):248-55.
Hampe CS, Ortqvist E, Rolandsson O, et al. Species-specific autoantibodies in type 1 diabe- tes. J Clin Endocrinol Metab. 1999;84(2):643-8.
Rodacki M, Zajdenverg L, Albernaz MS, et al. Relationship between the prevalence of anti- glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients. Braz J Med Biol Res. 2004;37(11):1645-50.
Sesterheim P, Saitovitch D, Staub, HL. Diabetes mellitus tipo 1: multifatores que conferem suscetibilidade à patogenia auto-imune [Type 1 diabetes mellitus: multifactors that confer susceptibility to the autoimmune pathogenesis]. Sci Med. 2007;17(4):212-7.
Silva MER, Mory D, Davini E. Marcadores genéticos e auto-imunes do diabetes melito tipo 1: da teoria para a prática (revisão) [Genetic and humoral autoimmunity markers of type 1 diabetes: from theory to practice: (review)]. Arq Bras Endocrinol Metab. 2008;52(2): 166-80.
Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002;51(6):1754-62.
Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci. 2002;958:117-30.
Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult- onset type 1 diabetes with rapid progression. Diabetes Care. 2003;26(2):452-7.
Schaan BDA, Harzheim E, Gus I. Perfil de risco cardíaco no diabetes mellitus e na glicemia de jejum alterada [Cardiac risk profile in diabetes mellitus and impaired fasting glucose]. Rev Saúde Pública = J Public Health. 2004;38(4):529-36.
Bem AF, Kunde J. A importância da determinação da hemoglobina glicada no monitoramen- to das complicações crônicas do diabetes mellitus [The importance of glycated hemoglobin determination in the management of chronic complications associated with diabetes melli- tus]. J Bras Patol Med Lab. 2006;42(3):185-91.
